ENVERIC BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.83 USD | +0.24% |
|
+5.33% | -36.15% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Ameri100 2018 Thi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.
Calendar
2024-05-27
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.83
USD
Average target price
9
USD
Spread / Average Target
+984.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.15% | 6.04M | |
| +64.23% | 55.07B | |
| -2.31% | 41.79B | |
| +44.36% | 40.22B | |
| -8.29% | 28.17B | |
| +11.97% | 26.28B | |
| -21.16% | 18.93B | |
| +7.54% | 13.03B | |
| +27.17% | 12.26B | |
| +25.72% | 12.21B |
- Stock Market
- Equities
- ENVB Stock
- News Enveric Biosciences, Inc.
- Transcript : AMERI Holdings, Inc., Q3 2018 Earnings Call, Nov 15, 2018
